A Recombinant hirudin (IK-HIR02) in healthy volunteers

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 3, 1996, Pages 140-149

  Schenk, J F ^a   Glusa, E ^b   Radziwon, P ^a,c   Butti, A ^d   Markwardt, F ^a   Breddin, H K ^a  

^a International Institute of Thrombosis and Vascular Diseases   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^d Iketon Farmaceutici   (Italy)

Author keywords

Anticoagulant effects; Bleeding time; Pharmacokinetics; Recombinant hirudin; Thrombin inhibition

Indexed keywords

IK HIR02; LEPIRUDIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTITHROMBINS; BLEEDING TIME; BLOOD COAGULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; FEMALE; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; RECOMBINANT PROTEINS;

EID: 0029943940     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217199     Document Type: Article

References (25)

1. Markwardt F: Untersuchungen über Hirudin. Naturwissenschaften 1955; 42:537-538.
2. Markwardt F: Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seylers Z Physiol Chem 1957;308:147-156.
3. Dodt J. Schmitz T, Schäfer T, Bergmann C: Expression, secretion and processing of hirudin in E. coli using the alkaline phosphatase signal sequence. FEBS Lett 1986:202:373-377.
4. Riehl-Bellon N, Carvalho D, Acker M, van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C: Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiae. Biochemistry 1989;28:2941-2949.
5. Skem T, Bischoff R. Jallat S, Dott K, Ali-Hadji D, Cless D, Kicny MP, Courtney M: Sulphation of hirudin in BHK cells. FEBS Lett 1990;275: 36-38.
6. Harvey RP, Degryse E, Stéfani L, Schamber F, Cazenave JP, Courtney M, Stolstoshev P, Lecocq JP: Cloning and expression of cDNA coding for the anticoagulant hirudin from the blood sucking leech, Him-do medicinalis. Proc Natl Acad Sei USA 1986;83:803-811.
7. Markwardt F: The development of hirudin as an antithrombotic drug. ThrombRes 1994;74:1-23.
8. Talbot MD, Ambler J. Butler KD, Findlay VS, Mitchell KA, Peters RF, Tweed MF, Wallis RB: Recombinant desulfatohirudin (CGP 39393): Anticoagulant and antithrombotic properties in vivo. Thromb Haemost 1989;61:77-80.
9. Markwardt F, Nowak G, Stürzebecher J. Griesbach U, Walsmann P, Vogel G: Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984;52: 160-163.
10. Markwardt F, Nowak G, Stürzebecher J: Clinical pharmacology of recombinant hirudin. Haemostasis 1991;21(suppl 1): 133-136.
11. Markwardt F, Nowak G, Stürze-bechcr J. Griesbach U, Walsmann P, Vogel G: Clinico-pharmacologi-cal studies with recombinant hirudin. Thromb Res 1988;52:393-400.
12. Mielke CH, Kancshiro MM, Maher IA, Weiner JM, Rapaport SI: The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969;34:204-215.
13. Verstraete M, Nurmohamed M, Kienast J. Siebeck M, Silling-Engel-hardt G, Büller H, Hoet B, Bichler J. Close P: Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J Am Coll Cardiol 1993;22:1080-1088.
14. Marbet GA, Verstraete M, Kienast J. Graf P, Hoet B, Tsakiris DA, Sil-ling-Engelhardt G, Close P: Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364-372.
15. Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ: The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990;78:268-270.
16. Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G: Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): An open pilot study. Thromb Haemost 1993;70:386-388.
17. Hoet B, Tornai I, Arnout J. Close P, Vermylcn J. Verstraete M: Open study of intravenous recombinant hirudin (CGP 39393) on platelet function and coagulation in healthy volunteers. Drug Invest 1994;7: 127-133.
18. Van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ. Su-ryapranata H, Zijlstra F, Close P, Rijnierse JM, Büller H, Scrruys PW: Safety and efficacy of recombinant hirudin (CGP 39393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 1993;88:2058-2066.
19. Schiele F, Vuillement A, Kramarz PH, Kieffer Y, Soria J. Soria C, Ca-mez A, Mirshahi MC, Bassand JP: A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 1994,71:558-562.
20. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P: Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994;72:227-231.
21. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maeurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Hora-cek T: Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. Circulation 1994;90:1638-1642.
22. Cannon CP, McCabe CH, Henry TD, Schweiger MJ. Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ. Rogers WJ. Williams DO, Braunwald E: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (T1MI)5 Trial. J Am Coll Cardiol 1994;23:993-1003.
23. Topol EJ. Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ. Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J: Recombinant hirudin for unstable angina pectoris, a multi-center, randomized angiographic trial. Circulation 1994;89:1557-1566.
24. Zoldhelyi P, Webster MWI, Fuster V. Grill DE, Gaspar D, Edwards SJ. Cabot CF, Chesebro J: Recombinant hirudin in patients with chronic, stable coronary artery disease. Circulation 1993:88:2015-2022.
25. Bucha E, Markwardt F, Nowak G: Hirudin in hemodialysis. Thromb Res 1990;60:445-455.